At the time of writing, AnaptysBio Inc [ANAB] stock is trading at $50.26, up 4.44%. An important factor to consider is whether the stock is rising or falling in short-term value. The ANAB shares have gain 11.17% over the last week, with a monthly amount glided 11.84%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Barclays started tracking the stock with Overweight rating on October 13, 2025, and set its price target to $78. On June 04, 2025, upgrade upgraded it’s rating to Buy but maintained its price target of $38 on the stock. Wolfe Research started tracking the stock assigning an Outtperform rating and suggested a price target of $25 on February 04, 2025. H.C. Wainwright downgraded its rating to a Neutral and reduced its price target to $19 on December 11, 2024. BTIG Research downgraded its rating to Neutral for this stock on December 02, 2024. In a note dated July 22, 2024, H.C. Wainwright initiated a Buy rating and provided a target price of $55 on this stock.
For the past year, the stock price of AnaptysBio Inc fluctuated between $12.21 and $52.47. Currently, Wall Street analysts expect the stock to reach $66.57 within the next 12 months. AnaptysBio Inc [NASDAQ: ANAB] shares were valued at $50.26 at the most recent close of the market. An investor can expect a potential return of 32.45% based on the average ANAB price forecast.
Analyzing the ANAB fundamentals
According to AnaptysBio Inc [NASDAQ:ANAB], the company’s sales were 169.47M for trailing twelve months, which represents an 154.26% jump. Gross Profit Margin for this corporation currently stands at 0.1% with Operating Profit Margin at -0.17%, Pretax Profit Margin comes in at -0.5%, and Net Profit Margin reading is -0.5%. To continue investigating profitability, this company’s Return on Assets is posted at -0.24, Equity is -11.01 and Total Capital is -0.09. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-11.78.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that AnaptysBio Inc [NASDAQ:ANAB] has a current ratio of 8.68. On the other hand, the Quick Ratio is 8.68, and the Cash Ratio is 2.88. Considering the valuation of this stock, the price to sales ratio is 8.21.
Transactions by insiders
Recent insider trading involved Lizzul Paul F., Chief Medical Officer, that happened on Jan 08 ’26 when 3650.0 shares were sold. Officer, Paul F. Lizzul completed a deal on Jan 08 ’26 to buy 3650.0 shares. Meanwhile, CHIEF FINANCIAL OFFICER MULROY DENNIS sold 2515.0 shares on Jan 08 ’26.
